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Severe adverse e¡ects have been described with protease inhi-
bitors (PIs), potent antiretroviral drugs used against advanced
infection with human immunode¢ciency virus (HIV).
Hyperglycemia and diabetes mellitus (DM) during treatment
with these drugs have been described previously, and the Food
and Drug Administration released a public health advisory
notice in 1997 [1,2]. The occurrence of these e¡ects, however,
seems relatively infrequent, and it is not clear whether the
treatment should be maintained.We observed three patients
who developed DM and hyperglycemiawith early onset when
treated with saquinavir, indinavir and ritonavir plus saquina-
vir.
From April 1996 through April 1998, 632 patients with
advanced HIV infection received treatment with PI in our
facility. Patients were assessed monthly during the ¢rst quarter
and every 3 months subsequently. Clinical evaluation, CD4
cell counts, viral load determination and hematologic and bio-
chemical analysis were performed at each visit. Adherence to
the treatment, e¤cacy and adverse e¡ects were registered.
When persistent basal hyperglycemia (glucose >140mg/dL)
was detected, peptide C, immunoreactive insulin, glycated
hemoglobin (HbAlc), islet cell antibodies (ICA), glutamic acid
decarboxylase antibodies (GADA) and levels of triglycerides
were assessed.
Three patients (0.47%) developed DM; all were males,
aged 34, 36 and 37 years, without a family history of diabetes,
and their glucose levels before treatment with PI were normal.
Two of them received prophylaxis with co-trimoxazole, but
no other drug was administered and diseases related to hyper-
glycemiawere not detected. Because of a deteriorating immu-
nologic situation, patients were treated with stavudine plus
lamivudine, and a PI was added: saquinavir (patient 1), indina-
vir (patient 2), and indinavir and later ritonavir plus saquinavir
(patient 3).
Antiretroviral treatment produced a favorable response in
patients 1 and 2. Patient 3 had received treatment with indina-
vir for 3 months without improvement, and with elevated
glucose basal levels. In this patient, the treatment was then
switched to ritonavir (400mg twice-daily) plus saquinavir
(400mg twice-daily), and 1 month later he was hospitalized
with acute pancreatitis and ketoacidosis.The time of treatment
before the onset of hyperglycemia ranged between 1 and 3
months. Data are shown inTable1.
Treatment with PI was discontinued in two patients (1 and
3). Hyperglycemiawas controlledwith diet and glibenclamide
(1month) in patient 1, and he remained well after cessation of
the hypoglycemic drug. Patients 2 and 3 needed insulin. Treat-
ment with PI was started again after withdrawal in patient 1
(after 6months without PI) and patient 3 (after 2months).
Patient 1was switched from saquinavir to indinavir, and nor-
mal basal glucose levels were maintained after 6months of fol-
low-up. In patient 3, after the acute episode of pancreatitis,
indinavir was reintroduced and hyperglycemia persists,
despite the administration of insulin (seeTable1).
Hyperglycemia and DM have been reported as adverse
e¡ects of treatment with PI, with a frequency ranging from
0.67% to 9.4% [3^10]. These e¡ects occur in the ¢rst few
months of treatment [3^10] as in our report, and seem not to
increase with time [3,7]. Cases with all currently used PIs
(saquinavir, ritonavir, indinavir and nel¢navir) have been
described [3^13], and no clear demographic, clinical or asso-
ciated drug risk factors for diabetes are consistently present [4].
A family history of diabetes has been reported in 17^66% of
patients [3, 5, 7], and several authors have described greater age
and impaired glucose tolerance prior to initiating therapy as
risk factors [14^16], but this was not our experience. New-
onset DM has also been described with several agents com-
monly used to manage HIV disease, such as pentamidine,
megestrol, ddI and prednisone [17^19], but not with co-tri-
moxazole, which was the only drug that our patient had
received.
The pathogenesis of this e¡ect is unknown. PIs block aspar-
tate protease, which is required to produce new virions.
Human processing of proinsulin to cleave C-peptide requires
serine endopeptidases (PC1/PC3 and PC2); these enzymes are
not a¡ected by protease inhibitors [20, 21]. In patients who are
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functionally de¢cient in these endopeptidases, however, the
mammalian homolog of yeast aspartic protease (YAP3p) may
play a more critical role in processing proinsulin [21^23] and
could be inhibited by the PI.The lack of ketosis in most of the
cases reported suggested a pathogenesis similar to that of
adult-onset, non-insulin-dependent diabetes and, in this
situation, high levels of C-peptide and insulin and impaired
oral glucose tolerance have been reported [6,7], revealing sig-
ni¢cant peripheral insulin resistance, as we observed in our
patients (Table1).
Recently, partial lipodystrophies have also been reported
after treatment with PIs and are associatedwith DMor insulin
resistance, with higher triglyceride and cholesterol levels [6, 8,
24], as we observed in our patients. Peripheral fat wasting (fat
loss from the face, limbs, and upper trunk), accumulation of
intra-abdominal fat, and fat in the breasts of women and over
the cervical vertebrae (`bu¡alo hump') have been described
[25^27]. Not all patients develop all features, but the data sug-
gest overall fat loss and a progressive process related to the use
of PIs. An interesting hypothesis has been proposed by Carr
et al [28]: HIV-1protease inhibitors have considerable homol-
ogy with the low-density lipoprotein-receptor-related pro-
tein (LRP) and with a C-terminal region of the cytoplasmic
retinoic-acid binding protein type 1 (CRABP-1), which pre-
sents retinoic acid to cytochrome P450 3A. This cytochrome
catalyzes the conversion of retinoic acid to cis-9-retinoic-acid,
which binds to the retinoid X receptor (RXR). In adipocyte
nuclei, RXR functions as a heterodimer with peroxisome-
proliferator-activated receptor type gamma (PPAR-g). Ligand
binding to RXRor PPAR-g inhibits adipocyte apoptosis and
upregulates adipocyte di¡erentiation and proliferation with
preferential expression of peripheral versus central fat. The
impaired CRABP1-mediated cis-9-retinoic acid stimulation
of RXR-PPAR-g induced by the PI then results in reduced
di¡erentiation and increased apoptosis of peripheral adipo-
cytes, with impaired fat storage and lipid release. The syn-
drome's severity is in part proportional to a PI's capacity to
inhibit cytochrome P450 3A, which is also inhibited by the
PI, especially ritonavir. In addition, the inhibition of the LRP
that is co-expressed on capillary endothelium with lipopro-
tein lipase (LPL) and cleaves fatty acids from circulating trigly-
cerides leads to secondary hyperlipidemia, central obesity and
breast fat deposition in the presence of estrogen. Insulin resis-
tance could be produced as a consequence of hyperlipidemia,
by interference with post-receptor insulin signaling, competi-
tion between glucose and lipid oxidation pathways in skeletal
muscles, or inhibition of glycogen synthase [29,30]. An alter-
native hypothesis proposed byMartinez and Gatell [31] specu-
lates that PI may also inhibit the insulin-degrading enzymes
(glutathione^insulin transhydrogenase or insulysin). The
hyperinsulinemia would stimulate hepatic lipogenesis, and
liver-derived triglycerides would be transported as very low-
density lipoproteins for deposition in adipose tissue. Insulin-
induced stimulation of lipoprotein lipase and inhibition of
hormone-sensitive lipase would result in a net increase of fat.
As long as hyperinsulinemia is maintained, it would ¢nally
lead to insulin resistance, and the net e¡ect at this stage would
be the inhibition of lipogenesis and the stimulation of lipoly-
sis, resulting in an inappropriate increase of plasma free fatty
acids. The increased availability of free fatty acids would
further increase hepatic triglyceride synthesis and enhance
hepatic glucose output, which would induce compensatory
insulin hypersecretion tomaintain glucose uptake homoeosta-
sis. In some predisposed individuals, overstimulation of b-
cells might lead to its failure and give rise to the emergence of
type 2 DM.
Therapeutic management of hyperglycemia seems di¤cult,
and no clear guides are provided. Good control of glucose
levels has been obtained with diet alone and, more frequently,
adding insulin and hypoglycemic agents, without discontinu-
ing treatment [3,4,6, 9,32], but in other reports controlwas dif-
¢cult if treatment was maintained [5,7]. New PPAR-g
agonists such as troglitazone have been recently used [33], but
it should be noted that the PI e¡ect on CRABP-1 and LRP is
Table 1 Details of treatment and outcome of three patients who developed hyperglycemia following dosage with protease inhibitors
Patient Drug
Timea
(days)
Glycemia
(mg/dL)
C-peptide
(ng/mL)
HbAlc
(%)
Insulin
(mc/mL)
GADA
(U/L)b
Triglycerides
(mg/dL)
1 Saquinavir 30 310 7.10 8.6 30.4 < 0.5 216
2 Indinavir 86 402 4.40 13.9 22.4 < 0.1 245
3c Indinavir
Saquinavir
 ritonavir
96
30
482 7.30 Not done 8.4 0.5 1073
aTime after the onset of treatment with protease inhibitor. bGlutamic acid decarboxylase antibodies. cThis patient developed acute
pancreatitis.
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not permanent, and hyperglycemia is therefore reversible if
PI treatment is stopped [5,6], as occurred in patient 1 in our
report. Surprisingly, in this patient, the reintroduction of a
di¡erent PI did not produce hyperglycemia, and the patient
maintained normal glucose levels with diet. Although meta-
bolic changes seem to be a class-speci¢c characteristic of PIs,
their CRABP-1 inhibitory e¡ect could be modulated for the
di¡erent degrees of cytochrome P450 inhibition. The use of
another PI does not appear to be an e¡ective strategy [34], but
some authors have reported bene¢t in switching to nel¢navir
from another PI [35,36].
Patients with advanced HIV disease clearly bene¢t from
protease inhibitors in terms of disease progression, survival
and reversal of opportunistic infections, but survival advan-
tage in early HIVdisease is still unproven. An alternative treat-
ment is now o¡ered with the use of non-nucleoside reverse
transcriptase inhibitors (NNRTIs). Reversal of metabolic
abnormalities in patients using PIs have been reported after
switching to nevirapine [37] or efavirenz [38]
In conclusion, treatment with PIs is associated with impor-
tant lipidemic alterations and impaired glucose homeostasis.
Although DM is relatively infrequent, clinicians need to be
aware of this potential complication and consider the risks and
bene¢ts of withdrawal of PI therapy if hyperglycemia occurs.
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